Claritev Stock Market Value
| CTEV Stock | 22.99 3.01 15.07% |
| Symbol | Claritev |
What growth prospects exist in Health Care Equipment & Supplies sector? Can Claritev capture new markets? Factors like these will boost the valuation of Claritev. Projected growth potential of Claritev fundamentally drives upward valuation adjustments. Valuation analysis balances hard financial data with qualitative growth assessments. While each Claritev valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Earnings Share (20.91) | Revenue Per Share | Quarterly Revenue Growth 0.067 | Return On Assets | Return On Equity |
Investors evaluate Claritev using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Claritev's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. External factors like market trends, sector rotation, and investor psychology can cause Claritev's market price to deviate significantly from intrinsic value.
It's important to distinguish between Claritev's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Claritev should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Claritev's market price signifies the transaction level at which participants voluntarily complete trades.
Claritev 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Claritev's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Claritev.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Claritev on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Claritev or generate 0.0% return on investment in Claritev over 90 days. Claritev is related to or competes with Goodrx Holdings, Opko Health, Evolent Health, Integra LifeSciences, Sana Biotechnology, Iradimed, and Axogen. Claritev is entity of United States. It is traded as Stock on NYSE exchange. More
Claritev Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Claritev's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Claritev upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 32.04 | |||
| Value At Risk | (12.87) | |||
| Potential Upside | 10.44 |
Claritev Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Claritev's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Claritev's standard deviation. In reality, there are many statistical measures that can use Claritev historical prices to predict the future Claritev's volatility.| Risk Adjusted Performance | (0.12) | |||
| Jensen Alpha | (1.28) | |||
| Total Risk Alpha | (1.66) | |||
| Treynor Ratio | (0.51) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Claritev's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Claritev February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.50) | |||
| Mean Deviation | 5.1 | |||
| Coefficient Of Variation | (614.99) | |||
| Standard Deviation | 6.98 | |||
| Variance | 48.75 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (1.28) | |||
| Total Risk Alpha | (1.66) | |||
| Treynor Ratio | (0.51) | |||
| Maximum Drawdown | 32.04 | |||
| Value At Risk | (12.87) | |||
| Potential Upside | 10.44 | |||
| Skewness | (0.66) | |||
| Kurtosis | 1.83 |
Claritev Backtested Returns
Claritev secures Sharpe Ratio (or Efficiency) of -0.0955, which signifies that the company had a -0.0955 % return per unit of standard deviation over the last 3 months. Claritev exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Claritev's mean deviation of 5.1, and Risk Adjusted Performance of (0.12) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 2.24, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Claritev will likely underperform. At this point, Claritev has a negative expected return of -0.61%. Please make sure to confirm Claritev's potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if Claritev performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.26 |
Poor predictability
Claritev has poor predictability. Overlapping area represents the amount of predictability between Claritev time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Claritev price movement. The serial correlation of 0.26 indicates that nearly 26.0% of current Claritev price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.26 | |
| Spearman Rank Test | 0.2 | |
| Residual Average | 0.0 | |
| Price Variance | 12.37 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Claritev Stock Analysis
When running Claritev's price analysis, check to measure Claritev's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Claritev is operating at the current time. Most of Claritev's value examination focuses on studying past and present price action to predict the probability of Claritev's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Claritev's price. Additionally, you may evaluate how the addition of Claritev to your portfolios can decrease your overall portfolio volatility.